Companies / MaxCyte / ExPERT STx™ Scalable static or flow electroporation
MaxCyte

ExPERT STx™ Scalable static or flow electroporation | MaxCyte

(0) Write Review

The industry’s leading scalable electroporation technology for high-yield, transient expression of complex proteins, vaccines and biologics.

  • Rapidly transfect from 75 thousand to 20 billion cells 
  • High efficiency enables flexible media strategies that can deliver significant cost savings 
  • Improved yields for decreased development timelines 
  • Proprietary Flow Electroporation™ Technology 
  • Faster production of stable clones 
  • ISO-certified and CE-marked

Request Quote

Supporting Documents

Scientific Brief

MaxCyte® Enabled Innovative SARS-CoV-2 Vaccine Development

You don't want to miss this!
To permanently access these supporting documents, fill out the short form below.

ALREADY ACCESSED THESE DOCUMENTS? SIGN IN

Reviews

(0) | Be the first to review this product
No reviews yet

ABOUT THE COMPANY

MaxCyte

At MaxCyte, we share your passion for the discovery, development, and manufacturing of next generation therapies, harnessing the power of living cells to transform lives. 

 

We know that every research journey is full of challenges, but we believe that transfecting cells shouldn’t be one of them. With over 20 years...

READ MORE
Scientific Products
  • See More
    • Upcoming Virtual Events
    Upcoming Webinars